ClinicalTrials.gg
RecruitingNCT07683585EDAMUpdated Jul 6, 2026

Comparative Effectiveness of Dual Antihypertensive Regimens in Patients After Percutaneous Coronary Intervention

An interventional study of Losartan + Hydrochlorothiazide and Amlodipine + Azilsartan in Hypertension, Coronary Arterial Disease and Percutaneous Coronary Intervention, sponsored by National Medical Research Center for Therapy and Preventive Medicine. Recruiting at 1 site in Russia. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by National Medical Research Center for Therapy and Preventive Medicine · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
207
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies testing losartan in Hypertension — 5 open to participants now, 5 under way, 1 of them phase 3. Losartan · Hypertension.

Planned enrollment
21st of 65
207 · median 100
Started
2026
with 1 other
No phase
6 of 65
1 open now
Registered
62nd of 65
by date

Among the 65 studies testing losartan in Hypertension, this one is the 21st largest by planned enrollment, is one of 2 that started in 2026, is one of 6 with no phase, and was the 62nd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 65 studies testing losartan in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About losartan

Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 50 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing losartan in Hypertension, or all of them as a file.
02

Study summary

This prospective randomized open-label study aims to compare the effectiveness of two dual antihypertensive therapy regimens in patients with arterial hypertension and coronary artery disease after elective percutaneous coronary intervention (PCI) with coronary artery stenting.

Patients requiring dual antihypertensive therapy will be randomized to receive either an angiotensin receptor blocker (ARB) combined with a thiazide diuretic or an ARB combined with a dihydropyridine calcium channel blocker.

The study will evaluate blood pressure control, angina symptoms, quality of life, need for treatment intensification, and healthcare utilization during follow-up. Clinical status will be assessed at discharge and during telemedicine follow-up visits at 2 weeks, 4 weeks, and 12 weeks after hospital discharge.

The primary endpoint is the percentage reduction in systolic and diastolic blood pressure. Secondary endpoints include frequency of angina episodes, exercise limitations, patient satisfaction with treatment, and medical consultations during follow-up.

The study is investigator-initiated and plans to enroll at least 207 participants.

03

Conditions studied

  • Hypertension
  • Coronary Arterial Disease
  • Percutaneous Coronary Intervention

Browse trials for

Keywords

  • Antihypertensive Therapy
  • Blood Pressure Control
  • Percuraneous Coronary Intervention
  • Angiotensin Receptor Blocker
  • Calcium Channel Blocker
  • Thiazide Diuretic
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 50 to 70 years
  • Arterial hypertension
  • Coronary artery disease
  • Hospitalization for elective percutaneous coronary intervention
  • Coronary artery stenting during the current hospitalization
  • Requirement for dual antihypertensive therapy
  • Treatment with beta-blockers, lipid-lowering therapy, and antiplatelet therapy
  • Ability and willingness to provide written

Exclusion criteria

Exclusion Criteria:

  • Refusal or inability to provide
  • Acute coronary syndrome
  • Active
  • Pulmonary embolism
  • Chronic kidney disease stage 4-5
  • Type 2 diabetes mellitus
  • or intolerance to study medications, including bilateral renal artery stenosis, hyperkalemia, hyperuricemia, or gout
  • Women of reproductive age
  • Permanent or persistent atrial fibrillation
  • Planned staged coronary stenting
  • Heart failure with reduced
  • Any other condition that, in the investigator's opinion, may interfere with participation in the study or interpretation of study results
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
207 participants (estimated)

Study arms

  • Active comparator
    ARB + Thiazide Diuretic

    Participants will receive dual antihypertensive therapy consisting of an angiotensin receptor blocker combined with a thiazide diuretic after elective percutaneous coronary intervention.

    Drug: Losartan + Hydrochlorothiazide

  • Active comparator
    ARB + Calcium Channel Blocker

    Participants will receive dual antihypertensive therapy consisting of an angiotensin receptor blocker combined with a dihydropyridine calcium channel blocker after elective percutaneous coronary intervention.

    Drug: Amlodipine + Azilsartan

Interventions

06

What researchers measure

Primary outcomes

  1. Change in office systolic and diastolic blood pressure (mmHg)

    Assessment of changes in systolic and diastolic blood pressure values compared with baseline measurements after initiation of dual antihypertensive therapy following elective percutaneous coronary intervention

    Time frame: 2 weeks, 4 weeks, and 12 weeks after hospital discharge

Secondary outcomes

  1. Physical Limitation Score of the Seattle Angina Questionnaire (SAQ)

    Assessment of exercise limitation using the Physical Limitation domain of the Seattle Angina Questionnaire (SAQ). Scores range from 0 to 100, with higher scores indicating less physical limitation and better functional status

    Time frame: 2 weeks, 4 weeks, and 12 weeks after hospital discharge

  2. Angina Frequency Score of the Seattle Angina Questionnaire (SAQ)

    Assessment of angina frequency using the Angina Frequency domain of the Seattle Angina Questionnaire (SAQ). Scores range from 0 to 100, with higher scores indicating fewer angina episodes and better angina control

    Time frame: 2 weeks, 4 weeks, and 12 weeks after hospital discharge

  3. Participants requiring healthcare utilization during follow-up

    Number of participants requiring at least one outpatient visit, emergency department visit, or hospitalization during follow-up

    Time frame: 2 weeks, 4 weeks, and 12 weeks after hospital discharge

07

Study locations

1 of 1 sites recruiting
  • National Medical Research Center for Therapy and Preventive Medicine
    Moscow, Russia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jul 2026, 3 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 3 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
Jul 6, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Jul 2026
CompletionEst.
Sep 2026
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07683585
Lead sponsor
National Medical Research Center for Therapy and Preventive Medicine
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Apr 1, 2026
Primary completion
Jul 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Jul 6, 2026

Study contacts

Elizaveta Rogozhkina
Contact
lizarogozkina@gmail.com
+7 (937) 104-73-31
Olga Dzhioeva
study chair · National Medical Research Center for Therapy and Preventive Medicine
Oxana Drapkina
principal investigator · National Medical Research Center for Therapy and Preventive Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Losartan · Hydrochlorothiazide · Amlodipine · Azilsartan

Start the discussion